

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

---

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT  
TO RULE 13a-16 or 15d-16 UNDER THE  
SECURITIES EXCHANGE ACT OF 1934

For the month of May, 2019

Commission File Number: 001-38452

**MEREO BIOPHARMA GROUP PLC**

(Translation of registrant's name into English)

**4<sup>th</sup> Floor, One Cavendish Place,  
London, W1G 0QF, United Kingdom**  
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**Mereo BioPharma Group plc**

**("Mereo" or the "Company")**

**Notification of Director Dealing**

**London, May 08, 2019** - Merco BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, received notification that on May 07, 2019, Anders Ekblom, Director of Merco, purchased 9340 American Depositary Shares (ADSs) at a price of USD5.457 per share.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

|    |   |   |           |
|----|---|---|-----------|
| 1  | Details of the person discharging managerial responsibilities   |   |           |
| a) | Name  | Anders Ekblom   |           |
| 2  | Reason for the notification   |   |           |
| a) | Position/status   | Director  |           |
| b) | Initial notification/ Amendment   | Initial notification  |           |
| 3  | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor   |   |           |
| a) | Name  | Mereo BioPharma Group plc                                   |           |
| b) | LEI   | 213800U8JQHIJOS5AS09  |           |
| 4  | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |   |           |
| a) | Description of the financial instrument, type of instrument and identification code   | MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY SHARES (ADSs) |           |
| b) | Nature of the transaction   | PURCHASE of ADSs  |           |
| c) | Price(s) and volume(s)  | Price(s)  | Volume(s) |
|    |   | USD5.46   | 9340      |
| d) | Aggregated information: volume, Price   | Aggregated volume: 9340                                     |           |
|    |   | Aggregated price: USD5.457                                  |           |
| e) | Date of the transaction   | 2019-05-07  |           |
| f) | Place of the transaction  | XNMS  |           |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 8, 2019

**MEREO BIOPHARMA GROUP PLC**

By: /s/ Richard Jones  
Name: Richard Jones  
Title: Chief Financial Officer

---